Fakher Rahim

@alnoor university

Department of Medical Laboratory Technologies,
Fakher Rahim



                 

https://researchid.co/bioinfo2003

RESEARCH, TEACHING, or OTHER INTERESTS

Biotechnology, Molecular Medicine, Genetics, Structural Biology

362

Scopus Publications

145187

Scholar Citations

100

Scholar h-index

327

Scholar i10-index

Scopus Publications

  • A meta-analysis of Preclinical Studies About The Effect of Spray-dried Porcine Plasma on Microbiota Composition
    Momunova Abdykerimovna, Fakher Rahim, Lyailya Alekesheva, Toguzbaeva Karlygash, Sokolov Dmitriy Konstantinovich, Kenesh Dzhusupov, and Abzal Zhumagaliuly

    Egyptian Knowledge Bank
    M ICROORGANISMS in the gut microbiota have developed alongside the host for thousands of years. Spray-dried porcine plasma (SDPP) increases development and immunity, making it a promising antibiotic replacement. In this systematic review and meta-analysis, we examined all available data on spray-dried porcine plasma’s immune response and microbiota composition alterations, which may affect antibacterial effectiveness. To achieve this goal, Cochrane central, ISI web of science (WOS), PubMed/Medline, Scopus, and EMBASE were systematically searched using standard terms. No language, study region, or research kind restrictions applied. Following the exclusion criteria, this meta-analysis included 11 papers on 474 animals’ important traits. Eleven studies involved 474 animals in this meta-analysis. The study involved eight pigs, three mice, one dog , bird, and fish. Firmicutes, Bacteroidetes , and other bacteria were more prevalent in SDPP-fed pig samples than in control diet samples. Proteobacteria, Tenericutes , and Actinobacteria were less common in SDPP-fed pig samples. SDPP did not affect growth performance measures compared to the control group. SDPP-exposed animals had higher Shannon and Simpson indices and more species, regardless of BW. In addition, treatment groups had similar colonic microbiota richness estimators (Chao 1). This study represents the first comprehensive meta-analysis to investigate the impact of SDPP s on immune response and microbiota composition alterations, which may affect antibacterial effectiveness in the peer-reviewed literature. The study’s findings demonstrated that the utilization of SDPP imposes little residual effects on the overall growth performance and increases the diversity and richness of bacterial communities, ultimately leading to alterations in the microbiota composition of the animals.

  • Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    Valery L Feigin, Theo Vos, Balakrishnan Sukumaran Nair, Simon I Hay, Yohannes Habtegiorgis Abate, Abdallah H A Abd Al Magied, Samar Abd ElHafeez, Atef Abdelkader, Mohammad-Amin Abdollahifar, Auwal Abdullahi,et al.

    Elsevier BV

  • Strategies to Strengthen Iraq's Primary Healthcare System: A Systematic Literature Review With Special Focus on Society 5.0
    Fakher Rahim, Karlygash Toguzbaeva, Arsen Aidaraliev, and Kenesh Dzhusupov

    Wiley
    ABSTRACTBackground and AimsThe primary healthcare (PHC) system is a comprehensive, equitable, and efficient approach to supporting health and social well‐being by offering prevention, treatment, and rehabilitation services close to living environments. The PHC system in Iraq is currently facing issues that limit its effectiveness and efficiency. This research aims to discover strategies to enhance the PHC system in Iraq.MethodsWe conducted a systematic search for articles on initiatives aimed at enhancing the PHC system, covering the period from 1980 to June 2024, using eight databases and Google Scholar. Included articles that met the criteria were analyzed with RevMan 5.3 software.ResultsA total of 18,705 articles were extracted. After removing duplicates and items without full text, 15,971 studies remained for title and abstract review, of which 14,175 were removed. Finally, 18 research articles related to PHC strengthening were used. Data collection methods included checking databases (12 studies), interviews (6 studies), focus groups (3 studies), questionnaires, and archival data (15 studies).ConclusionIn the context of Society 5.0, smart technology's practical applications in healthcare aim to enhance decision‐making, patient care, and service delivery. Smart technologies can help policymakers and health administrators make clinical decisions in complex care situations and streamline procedures like paperwork. This ultimately will improve the quality and effectiveness of healthcare services by providing accurate, timely, and personalized information to support decision‐making. When rebuilding and strengthening the PHC system, addressing the historical, social, cultural, and economic variables is important.Trial RegistrationNot applicable.

  • The global epidemiology and health burden of the autism spectrum: findings from the Global Burden of Disease Study 2021
    Damian F Santomauro, Holly E Erskine, Ana M Mantilla Herrera, Paul Anthony Miller, Jamileh Shadid, Hailey Hagins, Isaac Yeboah Addo, Qorinah Estiningtyas Sakilah Adnani, Bright Opoku Ahinkorah, Ayman Ahmed,et al.

    Elsevier BV

  • Ethnic Disparities in Cardiovascular Disease: A Comparative Analysis of Asian and Central Asian Populations
    Syed Azfar Hossain, Fakher Rahim, Zhyparkul Derbishalieva, and Kenesh Dzhusupov

    Springer Science and Business Media LLC

  • The Effect of Psychological Rehabilitation on Depression, Anxiety, and Stress of Hearing-Impaired Children using Dohsa-hou Method
    Fakher Rahim, Kenesh Dzhusupov, Karlygash Toguzbaeva, Svetlana Sultangaziyeva, and Roman Kalmatov

    Springer Science and Business Media LLC

  • Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
    Hmwe Hmwe Kyu, Avina Vongpradith, Regina-Mae Villanueva Dominguez, Jianing Ma, Samuel B Albertson, Amanda Novotney, Ibrahim A Khalil, Christopher E Troeger, Matthew C Doxey, Jorge R Ledesma,et al.

    Elsevier BV

  • Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    Peter J Leary, Megan Lindstrom, Catherine O Johnson, Sophia Emmons-Bell, Stuart Rich, Paul A Corris, Hilary M DuBrock, Corey E Ventetuolo, Yohannes Habtegiorgis Abate, Michael Abdelmasseh,et al.

    Elsevier BV

  • Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
    Sarah Brooke Sirota, Matthew C Doxey, Regina-Mae Villanueva Dominguez, Rose Grace Bender, Avina Vongpradith, Samuel B Albertson, Amanda Novotney, Katrin Burkart, Austin Carter, Parsa Abdi,et al.

    Elsevier BV

  • Global, regional, and national burden of household air pollution, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    Fiona B Bennitt, Sarah Wozniak, Kate Causey, Sandra Spearman, Chukwuma Okereke, Vanessa Garcia, Nadim Hashmeh, Charlie Ashbaugh, Atef Abdelkader, Meriem Abdoun,et al.

    Elsevier BV

  • HIV in Children Under 5 years of Age, and its Health Expenditure in Central Asian Countries
    Kozhobekov Kudaiberdi Gaparalievich, Fakher Rahim, Roman Kalmatov, Kenesh Dzhusupov, and Bugubaeva Makhabat Mitalipovna

    Springer Science and Business Media LLC

  • Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021
    Michael Benjamin Arndt, Yohannes Habtegiorgis Abate, Mohsen Abbasi-Kangevari, Samar Abd ElHafeez, Michael Abdelmasseh, Sherief Abd-Elsalam, Deldar Morad Abdulah, Rizwan Suliankatchi Abdulkader, Hassan Abidi, Olumide Abiodun,et al.

    Elsevier BV

  • Global, regional, and national burden of HIV/AIDS, 1990–2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021
    Austin Carter, Meixin Zhang, Khai Hoan Tram, Magdalene K Walters, Deepa Jahagirdar, Edmond D Brewer, Amanda Novotney, Dylan Lasher, Emmanuel A Mpolya, Avina Vongpradith,et al.

    Elsevier BV

  • Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
    Dana Bryazka, Marissa B Reitsma, Yohannes Habtegiorgis Abate, Abdallah H A Abd Al Magied, Atef Abdelkader, Arash Abdollahi, Meriem Abdoun, Rizwan Suliankatchi Abdulkader, Roberto Ariel Abeldaño Zuñiga, E S Abhilash,et al.

    Elsevier BV

  • Retraction Note: Association of the corona virus (Covid-19) epidemic with environmental risk factors (Environmental Science and Pollution Research, (2023), 30, 21, (60314-60325), 10.1007/s11356-023-26647-5)
    Abdolkazem Neisi, Gholamreza Goudarzi, Mohammad Javad Mohammadi, Yasser Tahmasebi, Fakher Rahim, Zeinab Baboli, Mohsen Yazdani, Armin Sorooshian, Somayeh Alizade Attar, Kambiz Ahmadi Angali,et al.

    Springer Science and Business Media LLC

  • Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    Valery L Feigin, Melsew Dagne Abate, Yohannes Habtegiorgis Abate, Samar Abd ElHafeez, Foad Abd-Allah, Ahmed Abdelalim, Atef Abdelkader, Michael Abdelmasseh, Sherief Abd-Elsalam, Parsa Abdi,et al.

    Elsevier BV

  • Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
    Mohsen Naghavi, Stein Emil Vollset, Kevin S Ikuta, Lucien R Swetschinski, Authia P Gray, Eve E Wool, Gisela Robles Aguilar, Tomislav Mestrovic, Georgia Smith, Chieh Han,et al.

    Elsevier BV

  • Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
    Rose Grace Bender, Sarah Brooke Sirota, Lucien R Swetschinski, Regina-Mae Villanueva Dominguez, Amanda Novotney, Eve E Wool, Kevin S Ikuta, Avina Vongpradith, Emma Lynn Best Rogowski, Matthew Doxey,et al.

    Elsevier BV

  • Global pattern, trend, and cross-country inequality of early musculoskeletal disorders from 1990 to 2019, with projection from 2020 to 2050
    Yingzhao Jin, Cui Guo, Mohammadreza Abbasian, Mitra Abbasifard, J. Haxby Abbott, Auwal Abdullahi, Aidin Abedi, Hassan Abidi, Hassan Abolhassani, Eman Abu-Gharbieh,et al.

    Elsevier BV

  • Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020
    Konrad Pesudovs, Van Charles Lansingh, John H. Kempen, Ian Tapply, Arthur G. Fernandes, Maria V. Cicinelli, Alessandro Arrigo, Nicolas Leveziel, Paul Svitil Briant, Theo Vos,et al.

    Springer Science and Business Media LLC
    Abstract Background To estimate global and regional trends from 2000 to 2020 of the number of persons visually impaired by cataract and their proportion of the total number of vision-impaired individuals. Methods A systematic review and meta-analysis of published population studies and gray literature from 2000 to 2020 was carried out to estimate global and regional trends. We developed prevalence estimates based on modeled distance visual impairment and blindness due to cataract, producing location-, year-, age-, and sex-specific estimates of moderate to severe vision impairment (MSVI presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60). Estimates are age-standardized using the GBD standard population. Results In 2020, among overall (all ages) 43.3 million blind and 295 million with MSVI, 17.0 million (39.6%) people were blind and 83.5 million (28.3%) had MSVI due to cataract blind 60% female, MSVI 59% female. From 1990 to 2020, the count of persons blind (MSVI) due to cataract increased by 29.7%(93.1%) whereas the age-standardized global prevalence of cataract-related blindness improved by −27.5% and MSVI increased by 7.2%. The contribution of cataract to the age-standardized prevalence of blindness exceeded the global figure only in South Asia (62.9%) and Southeast Asia and Oceania (47.9%). Conclusions The number of people blind and with MSVI due to cataract has risen over the past 30 years, despite a decrease in the age-standardized prevalence of cataract. This indicates that cataract treatment programs have been beneficial, but population growth and aging have outpaced their impact. Growing numbers of cataract blind indicate that more, better-directed, resources are needed to increase global capacity for cataract surgery.

  • Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020
    , João M. Furtado, Jost B. Jonas, Ian Tapply, Arthur G. Fernandes, Maria Vittoria Cicinelli, Alessandro Arrigo, Nicolas Leveziel, Serge Resnikoff, Hugh R. Taylor,et al.

    Springer Science and Business Media LLC
    Abstract Background We aimed to update estimates of global vision loss due to age-related macular degeneration (AMD). Methods We did a systematic review and meta-analysis of population-based surveys of eye diseases from January, 1980, to October, 2018. We fitted hierarchical models to estimate the prevalence of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness ( < 3/60) caused by AMD, stratified by age, region, and year. Results In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77). The crude prevalence of AMD-related blindness in 2020 (among those aged ≥ 50 years) was 0.10% (0.07 to 0.12) globally, and the region with the highest prevalence of AMD-related blindness was North Africa/Middle East (0.22%; 0.16 to 0.30). Age-standardized prevalence (using the GBD 2019 data) of AMD-related MSVI in people aged ≥ 50 years in 2020 was 0.34% (0.27 to 0.41) globally, and the region with the highest prevalence of AMD-related MSVI was also North Africa/Middle East (0.55%; 0.44 to 0.68). From 2000 to 2020, the estimated crude prevalence of AMD-related blindness decreased globally by 19.29%, while the prevalence of MSVI increased by 10.08%. Conclusions The estimated increase in the number of individuals with AMD-related blindness and MSVI globally urges the creation of novel treatment modalities and the expansion of rehabilitation services.

  • Correction to: Global estimates on the number of people blind or visually impaired by cataract_ a meta-analysis from 2000 to 2020 (Eye, (2024), 10.1038/s41433-024-02961-1)
    , Konrad Pesudovs, Van Charles Lansingh, John H. Kempen, Ian Tapply, Arthur G. Fernandes, Maria Vittoria Cicinelli, Alessandro Arrigo, Nicolas Leveziel, Serge Resnikoff,et al.

    Springer Science and Business Media LLC

  • Global estimates on the number of people blind or visually impaired by glaucoma: A meta-analysis from 2000 to 2020
    , Rupert R. A. Bourne, Jost B. Jonas, David Friedman, Vinay Nangia, Alain Bron, Ian Tapply, Arthur G. Fernandes, Maria Vittoria Cicinelli, Alessandro Arrigo,et al.

    Springer Science and Business Media LLC
    Abstract Objectives To estimate global and regional trends from 2000 to 2020 of the number of persons visually impaired by glaucoma and their proportion of the total number of vision-impaired individuals. Methods A systematic review and meta-analysis of published population studies and grey literature from 2000 to 2020 was carried out to estimate global and regional trends in number of people with vision loss due to glaucoma. Moderate or severe vision loss (MSVI) was defined as visual acuity of 6/60 or better but <6/18 (moderate) and visual acuity of 3/60 or better but <6/60 (severe vision loss). Blindness was defined as presenting visual acuity <3/60. Results Globally, in 2020, 3.61 million people were blind and nearly 4.14 million were visually impaired by glaucoma. Glaucoma accounted for 8.39% (95% uncertainty intervals [UIs]: 6.54, 10.29) of all blindness and 1.41% (95% UI: 1.10, 1.75) of all MSVI. Regionally, the highest proportion of blindness relating to glaucoma was found in high-income countries (26.12% [95% UI: 20.72, 32.09]), while the region with the highest age-standardized prevalence of glaucoma-related blindness and MSVI was Sub-Saharan Africa. Between 2000 and 2020, global age-standardized prevalence of glaucoma-related blindness among adults ≥50 years decreased by 26.06% among males (95% UI: 25.87, 26.24), and by 21.75% among females (95% UI: 21.54, 21.96), while MSVI due to glaucoma increased by 3.7% among males (95% UI: 3.42, 3.98), and by 7.3% in females (95% UI: 7.01, 7.59). Conclusions Within the last two decades, glaucoma has remained a major cause of blindness globally and regionally.

  • Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
    Jorge R Ledesma, Jianing Ma, Meixin Zhang, Ann V L Basting, Huong Thi Chu, Avina Vongpradith, Amanda Novotney, Kate E LeGrand, Yvonne Yiru Xu, Xiaochen Dai,et al.

    Elsevier BV

  • The Impact of Human Cystic Echinococcosis in the Central Asian Region, 1990-2019
    Fakher Rahim, Karlygash Toguzbaeva, and Kenesh O. Dzhusupov

    Galenos Yayinevi
    Objective This research aims to update knowledge on the regional and national sickness burden attributable to cystic echinococcosis (CE) from 1990 to 2019, as well as epidemiology and disease control, with a particular emphasis on the People's Central Asian Regions. Methods We calculated the morbidity, mortality, and disability-adjusted life years at the global, regional, and national levels for CE in all central Asian countries from 1990 to 2019, and we analyzed the association between GDP per capita and the disease burden of CE. Results In 2019, the three greatest numbers of CE cases were recorded in Kazakhstan [23986; 95% uncertainty interval (UI); 19796; 28908]; Uzbekistan (41079; 18351; 76048); and Tajikistan (10887; 4891; 20170) among all 9 countries. The three countries with the greatest ASIR of CE were estimated to be Kazakhstan (127.56; 95% UI: 105.34-153.8), Uzbekistan (123.53; 95% UI: 58.65-219.16), and Tajikistan (121.88; 58.57-213.93). Kyrgyzstan, Tajikistan, and Uzbekistan had the biggest increases (125%, 97%, and 83%, respectively) in the number of incident cases of CE, whereas Georgia, Kazakhstan, and Armenia saw the largest decreases (45%, 8%, and 3%, respectively). Conclusion To reduce the illness burden caused by CE, our findings may help public health professionals and policymakers design cost-benefit initiatives. To lessen the impact of CE on society, it is suggested that more money be given to the region's most endemic nations. Echinococcosis, cystic, negative health effects, life-years lost due to disability, rate of occurrence as a function of age, rate of death as a function of age.

RECENT SCHOLAR PUBLICATIONS

  • A meta-analysis of Preclinical Studies About The Effect of Spray-dried Porcine Plasma on Microbiota Composition
    MA Abdykerimovna, F Rahim, L Alekesheva, T Karlygash, ...
    Egyptian Journal of Veterinary Sciences 56 (4), 679-690 2025

  • HIV in Children Under 5 years of Age, and its Health Expenditure in Central Asian Countries.
    R Gaparalievich, K.K., Rahim, F., Kalmatov
    Indian J Pediatr 2025

  • Strategies to Strengthen Iraq's Primary Healthcare System: A Systematic Literature Review With Special Focus on Society 5.0
    F Rahim, K Toguzbaeva, A Aidaraliev, K Dzhusupov
    Public Health Challenges 4 (1), e70033 2025

  • Ethnic Disparities in Cardiovascular Disease: A Comparative Analysis of Asian and Central Asian Populations
    SA Hossain, F Rahim, Z Derbishalieva, K Dzhusupov
    Journal of Racial and Ethnic Health Disparities, 1-12 2025

  • Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    VL Feigin, T Vos, BS Nair, SI Hay, YH Abate, AHA Abd Al Magied, ...
    The Lancet Public Health 2025

  • The global epidemiology and health burden of the autism spectrum: findings from the Global Burden of Disease Study 2021
    DF Santomauro, HE Erskine, AMM Herrera, PA Miller, J Shadid, H Hagins, ...
    The Lancet Psychiatry 12 (2), 111-121 2025

  • The Effect of Psychological Rehabilitation on Depression, Anxiety, and Stress of Hearing-Impaired Children using Dohsa-hou Method
    SSRK Fakher Rahim, Kenesh Dzhusupov, Karlygash Toguzbaeva
    Journal of Psychosocial Rehabilitation and Mental Health 2025

  • Blindness and Vision Loss in Central Asian Countries
    K Rahim, F., Toguzbaeva, K., Dzhusupov
    The Palgrave Encyclopedia of Disability 2025

  • Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    PJ Leary, M Lindstrom, CO Johnson, S Emmons-Bell, S Rich, PA Corris, ...
    The Lancet Respiratory Medicine 13 (1), 69-79 2025

  • Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
    SB Sirota, MC Doxey, RMV Dominguez, RG Bender, A Vongpradith, ...
    The Lancet Infectious Diseases 25 (1), 36-51 2025

  • Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021
    MB Arndt, YH Abate, M Abbasi-Kangevari, S Abd ElHafeez, ...
    The Lancet 404 (10471), 2543-2583 2024

  • Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic
    K Hmwe Hmwe, A Vongpradith, RMV Dominguez, J Ma, SB Albertson, ...
    Elsevier 2024

  • Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic
    HH Kyu, A Vongpradith, RMV Dominguez, J Ma, SB Albertson, ...
    The Lancet Infectious Diseases 2024

  • Global, regional, and national burden of HIV/AIDS, 1990–2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021
    A Carter, M Zhang, KH Tram, MK Walters, D Jahagirdar, ED Brewer, ...
    The Lancet HIV 11 (12), e807-e822 2024

  • The Impact of Combined Cranberry Supplementation and Weight Loss Diet on Inflammatory, Antioxidant, and Apoptosis Biomarkers in Patients with Non-Alcoholic Fatty Liver Disease
    R Hormoznejad, MM Shahi, S Mahboobi, F Rahim, B Helli, P Alavinejad, ...
    Journal of Nutrition and Food Security 2024

  • Retraction Note: Association of the corona virus (Covid-19) epidemic with environmental risk factors
    A Neisi, G Goudarzi, MJ Mohammadi, Y Tahmasebi, F Rahim, Z Baboli, ...
    Environmental Science and Pollution Research 31 (48), 58667-58668 2024

  • Vaping Possible Negative Effects on Lungs: State-of-the-Art From Lung Capacity Alteration to Cancer
    Fakher Rahim, Karlygash Toguzbaeva, Dmitriy Sokolov, Kenesh O. Dzhusupov ...
    Cureus 2024

  • Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease
    D Bryazka, MB Reitsma, YH Abate, AHA Abd Al Magied, A Abdelkader, ...
    The lancet Public health 9 (10), e729-e744 2024

  • Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    VL Feigin, MD Abate, YH Abate, S Abd ElHafeez, F Abd-Allah, ...
    The Lancet Neurology 23 (10), 973-1003 2024

  • Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
    M Naghavi, SE Vollset, KS Ikuta, LR Swetschinski, AP Gray, EE Wool, ...
    The Lancet 404 (10459), 1199-1226 2024

MOST CITED SCHOLAR PUBLICATIONS

  • Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic
    SL James, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ...
    The Lancet 392 (10159), 1789-1858 2018
    Citations: 10549

  • Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
    T Vos, SS Lim, C Abbafati, KM Abbas, M Abbasi, M Abbasifard, ...
    The lancet 396 (10258), 1204-1222 2020
    Citations: 10137

  • Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study
    GA Roth, GA Mensah, CO Johnson, G Addolorato, E Ammirati, ...
    Journal of the American college of cardiology 76 (25), 2982-3021 2020
    Citations: 9146

  • Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to
    C Fitzmaurice, C Allen, RM Barber, L Barregard, ZA Bhutta, H Brenner, ...
    JAMA oncology 3 (4), 524-548 2017
    Citations: 8271

  • Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and
    JD Stanaway, A Afshin, E Gakidou, SS Lim, D Abate, KH Abate, ...
    The lancet 392 (10159), 1923-1994 2018
    Citations: 8045

  • Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of
    GA Roth, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ...
    The lancet 392 (10159), 1736-1788 2018
    Citations: 7500

  • Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
    CJL Murray, AY Aravkin, P Zheng, C Abbafati, KM Abbas, ...
    The lancet 396 (10258), 1223-1249 2020
    Citations: 7406

  • Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study
    KE Rudd, SC Johnson, KM Agesa, KA Shackelford, D Tsoi, DR Kievlan, ...
    The Lancet 395 (10219), 200-211 2020
    Citations: 5971

  • Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
    M Naghavi, AA Abajobir, C Abbafati, KM Abbas, F Abd-Allah, SF Abera, ...
    The lancet 390 (10100), 1151-1210 2017
    Citations: 5039

  • Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
    VL Feigin, E Nichols, T Alam, MS Bannick, E Beghi, N Blake, ...
    The Lancet Neurology 18 (5), 459-480 2019
    Citations: 4949

  • Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of
    GBD Collaborators
    The Lancet 385 (9963), 117-171 2015
    Citations: 4914

  • Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990
    HH Kyu, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ...
    The Lancet 392 (10159), 1859-1922 2018
    Citations: 3836

  • Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
    MG Griswold, N Fullman, C Hawley, N Arian, SRM Zimsen, HD Tymeson, ...
    The Lancet 392 (10152), 1015-1035 2018
    Citations: 3503

  • Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
    E Nichols, JD Steinmetz, SE Vollset, K Fukutaki, J Chalek, F Abd-Allah, ...
    The Lancet Public Health 7 (2), e105-e125 2022
    Citations: 3188

  • Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
    VL Feigin, BA Stark, CO Johnson, GA Roth, C Bisignano, GG Abady, ...
    The Lancet Neurology 20 (10), 795-820 2021
    Citations: 2600

  • Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
    GBD 2019 Stroke Collaborators
    The Lancet. Neurology 20 (10), 795 2021
    Citations: 2438

  • The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease
    S Alatab, SG Sepanlou, K Ikuta, H Vahedi, C Bisignano, S Safiri, ...
    The Lancet gastroenterology & hepatology 5 (1), 17-30 2020
    Citations: 2125

  • Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
    JB Soriano, PJ Kendrick, KR Paulson, V Gupta, EM Abrams, RA Adedoyin, ...
    The Lancet Respiratory Medicine 8 (6), 585-596 2020
    Citations: 1877

  • Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis
    JD Steinmetz, RRA Bourne, PS Briant, SR Flaxman, HRB Taylor, ...
    The Lancet Global Health 9 (2), e144-e160 2021
    Citations: 1856

  • Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
    CO Johnson, M Nguyen, GA Roth, E Nichols, T Alam, D Abate, ...
    The Lancet Neurology 18 (5), 439-458 2019
    Citations: 1607